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Case presentation
A 54-year-old man was admitted to the hospital in an obtunded state.
A diagnosis of diabetes mellitus had been made at the age of 43, after he
had experienced polydypsia, polyuria, and a IS-lb. weight loss. In the
11 years after the diagnosis of diabetes was established, he was
admitted to the hospital several times for acute and chronic alcoholism
and cellulitis of the face. On one of these admissions, his blood glucose
was 304 mg/dl and plasma bicarbonate was 14 mEq/liter. Treatment
with 60 units of regular insulin and 3 liters of normal saline over an 8-
hour period restored the blood sugar and bicarbonate concentration to
normal. The patient was discharged on 40 units of NPH insulin daily,
but the physicians who examined him later in the clinic believed he was
not complying with this therapeutic program.
Before admission, the patient had been drinking heavily, and on the
morning of admission he was found in bed, incontinent, confused, and
difficult to arouse. On admission he was grossly confused, unable to
give a history, and combative. He was slightly obese and was taking 24
deep breaths per minute. The blood pressure was 110/70 mm Hg, and
the heart rate was 104 beats per minute. The skin turgor was poor. His
breath was fetid but acetone could not be detected. The neck veins were
flat. There was a grade 1/VI precordial systolic murmur. The lungs were
clear except for scattered ronchi. The liver, which could be percussed 4
finger breadths below the right costal margin, seemed slightly tender.
Ankle reflexes were absent, and pain sensation in the lower extremities
was markedly decreased.
Laboratory findings included: hematocrit, 41% with normal indices;
white blood cell count, 8400 per mm3 with a normal differential; blood
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glucose, 193 mg/dl; BUN, 32 mg/dl; and serum creatinine, 1.6 mg/dl.
Electrolyte values included: sodium, 141 mEq/liter; potassium, 5.1
mEq/liter; chloride, 105 mEq/liter; and bicarbonate, 12 mEq/liter. The
blood pH was 7.30 and the PaCO2 was 25 mm Hg. Ketones were
positive in 1:4 dilution. Subsequent enzymatic analysis gave values of
plasma acetoacetate, 1.2 mEq/liter; 3-hydroxybutyrate, 9.0 mEq/liter;
and lactate, 1.2 mEq/liter.
Treatment with intermittent small doses of regular insulin (10 units
per hour three times) and with intravenous glucose and one-half normal
saline reversed the metabolic abnormalities within 8 hours.
Discussion
Dr. George F. Cahill, Jr. (Professor of Medicine, Harvard
Medical School; Director of Research, Howard Hughes Medi-
cal Institute; and Physician, Brigham and Women's Hospital,
Boston): This man had a history of diabetes and the classic
syndrome of weight loss, polydypsia, and polyuria 11 years
prior to the present admission. He was and is slightly obese.
The relatively mild course of his metabolic disorder permitted
him to stop insulin therapy without becoming ketotic. If not for
the initial event and the current episode of ketosis, he would be
classified as having typical non-insulin-dependent diabetes mel-
litus (NIDDM). The type of diabetes in this patient contrasts
with the other common variety, insulin-dependent diabetes
mellitus (IDDM), which is more frequent in youth and is
associated with a progressive viral and/or autoimmune destruc-
tion of the beta cells. The latter form of the disease necessitates
daily insulin injections to prevent gross metabolic decompensa-
tion and ketoacidosis because a total or nearly total lack of
endogenous insulin production occurs within several years.
Thus this patient is a non-insulin-dependent or "maturity-
onset" diabetic, whose only overt symptom of diabetes was
soft-tissue infection of the face, a problem probably also related
to poor hygiene. Although the diabetes was reasonably well
controlled, the patient did exhibit a neurologic deficit in his
lower extremities. This condition also was probably exacerbat-
ed by his alcohol intake: alcohol and diabetes act synergistically
in causing peripheral neuropathy.
On admission, the patient was somewhat hyperpneic, and
metabolic acidosis was discovered to be the cause of the
hyperventilation. Ketosis was the cause of the acidosis, as
evidenced by the elevated values of -hydroxybutyrate, 9 mM/
liter, and acetoacetate (AcAc), 1.2 mM/liter, Plasma lactate was
only 1.2 mM/liter. Thus he had moderate ketoacidosis but his
blood glucose concentration was only 193 mg/dl. One might
have expected a glucose value of 300 or 400 mg/dl, or even
higher perhaps, especially in light of the slightly elevated blood
urea and serum creatinine levels. He was treated appropriately
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Fig. 1. Interrelationship between acetoacetate (AcAc) and I3-hydroxy-
butyrate (BOHB), the reaction catalyzed by the enzyme f3-hydroxybu-
tyrate dehydrogenase with NAD as acceptor to produce NADH plusH. Also shown is the nonenzymatic decarboxylation of AcAc to
acetone, an irreversible step.
with small doses of insulin, 5 to 10 units initially, and he was
given both glucose and saline; the chemical abnormalities were
corrected in several hours. Had the glucose levels been in the
overtly diabetic range of 400 mg/dl or higher, it would have been
appropriate to treat him with larger quantities of insulin given
either intramuscularly or intravenously. Although the patient
was somewhat hyperglycemic, he did not have bona fide
diabetic ketoacidosis and thus he was appropriately treated
with small doses of insulin, saline, and glucose from the start.
What was the pathogenesis of the metabolic disorder in this
patient? He had not been eating, and the ketosis probably could
be attributed partially to simple starvation. But it takes 1 to 2
weeks of total starvation to cause such a severe degree of
ketosis [1, 21. In fact, in the fasting patient, increased excretion
of ammonia by the kidney counterbalances the effect of the
increased acid production, thus limiting the severity of acidosis.
Another factor contributing to ketosis in this patient was the
alcohol intake [3—5]. Alcohol is metabolized in the liver to form
acetaldehyde and acetate, and the latter is released into the
circulation for metabolism by other tissues. Flooding of the
liver by acetate results in the production of ketoacids, especial-
ly 3-hydroxybutyrate (BOHB), and this increased acetate load
probably contributed to the ketoacidosis. In the presence of
excessive alcohol metabolism, reduced NAD (i.e., NADH)
accumulates and leads to a preferential conversion of pyruvic
acid to lactic acid. Although plasma lactate was nearly within
the normal range when this patient was examined, the plasma
lactate level might have been higher earlier. The slightly elevat-
ed BOHB/AcAc ratio (normal = 4/1) supports this contention
because these two substrates, like lactate and pyruvate, are a
redox couple. The lactate/pyruvate ratio represents the mean
body cytosolic redox potential, and the BOHB/AcAc ratio
refers to the mean of the mitochondrial redox potential. With
anoxia or with an excessive production of reducing equivalents,
as with alcohol metabolism, both ratios increase.
In sum, the patient had mild ketoacidosis that probably
resulted from three processes, each leading to increased hepatic
ketone production: starvation, alcohol consumption, and possi-
bly diabetic decompensation.
Ketoacid metabolism. The intermediary metabolism of the
ketoacids has been reviewed in great detail in several recent
articles. Hepatic ketogenesis was discussed extensively by
McGarry, Mannaerts, and Foster [6—8], and the peripheral
metabolism of the ketoacids and their effects on other sub-
strates was reviewed by Robinson and Williamson [9]. Fenselau
detailed the biochemical reactions involved in ketogenesis and
ketoacid metabolism [10], and Liljenquist discussed ketoacid
regulation [11] in Brownlee's series on diabetes mellitus [121.
These reviews permit me to concentrate on the pathways of
ketogenesis, and I will emphasize the issues concerning sub-
strate and sites of hormonal control.
Acetoacetate and -hydroxybutyrate are the principal 'ke-
tone" products and are interconverted by a single step, an
oxidation-reduction with NAD and NADH as cofactors (Fig.
1). The enzyme for this interconversion, 3-hydroxybutyrate
dehydrogenase, is located primarily inside mitochondria, as
compared with lactate dehydrogenase, which resides in the
cytosol. Thus the BOHB/AcAc ratio reflects the mitochondrial
NADH/NAD ratio, and the lactate/pyruvate (L/P) ratio is
indicative of the same ratio in the cytosol. The third "ketone,"
acetone, is thought to be the product of a nonenzymatic
decarboxylation of AcAc, although its production still could be
enzymatically catalyzed. Acetone production is, therefore, a
function of the level of AcAc and the duration of its elevation;
the presence of acetone is thus indicative of a sustained, severe
ketoacidosis. Reichard et al recently showed that about one-
third of AcAc metabolically produced is decarboxylated to
acetone and, surprisingly, about two-thirds of the acetone is
recovered as glucose [13, 14]. This is a novel observation that
disproves the old adage that fat cannot be converted into
carbohydrate in humans. Although this route of conversion of
fatty acid to acetate to acetoacetate to acetone to glucose is a
circuitous one, it might play a very important role in prolonged
fasting in humans.
Acetoacetate and -hydroxbutyrate are produced in approxi-
mately equal amounts in humans and are made primarily by the
liver [15]. No other tissue makes significant amounts of these
ketones except muscle and kidney, which produce them only
occasionally and in small amounts. Blood levels of AcAc and
BOHB in the usual postabsorptive state are less than 0.1 mM!
liter, and if large carbohydrate loads are administered, these
levels can fall to as low as 0.0 10 mM/liter. Such low basal levels
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Fig. 2. Physiologic ranges of circutat,ng substrates in normal humans
expressed on a logarithmic scale. Of note is the narrow range of glucose
concentrations and the three orders of magnitude variation in the
concentration of BOHB.
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might consist of products of branched-chain amino acid catabo-
lism instead of by-products of hepatic acetate metabolism; thus,
fat-derived ketogenesis under these circumstances is probably
near zero. In fasting humans, AcAc and BOHB levels rise to
1.2—1.6 and 6—8 mM/liter, respectively, but it takes ito 2 weeks
to reach this plateau. Thus the variation in their concentrations
may be 3 orders of magnitude; this extreme range of concentra-
tion makes these compounds unique compared to all other
metabolic fuels. For example, glucose levels vary between 4
and 6 mM; other fuels such as alanine, leucine, lactate, and
fatty acids vary by less than one order of magnitude (Fig. 2).
Acetoacetate and BOHB should be considered overflow
products of the hepatic acetyl CoA pool. When CoA production
surpasses its two routes of assimilation, ketoacid synthesis and
release occur. As noted, the biochemical steps have been
elucidated elsewhere in extenso [9, 10]. Figure 3 summarizes
hepatic metabolism; Figure 4 contains a modified schema for
the fasted (low-insulin) state. Free fatty acids released from
adipose tissue are carried in plasma to the liver and by transport
processes not yet clarified enter the liver cytosol where they are
activated to their acyl CoA derivations. These derivatives are
transacylated and the fatty acids are transported into the
mitochondria as the carnitine ester, The acyl CoA ester is
regenerated inside the mitochondria; then the classic "beta"
oxidation of the long-chain fatty acyl CoA ester takes place,
producing a number of acetyl CoAs and equal quantities of the
reduced coenzymes NADH and FADH. These coenzymes
donate their electrons to the mitochondrial energy chain, pro-
ducing ATP and yielding their protons to oxygen to form water.
One-third of the potential metabolic energy of a long-chain fatty
acid is produced in this manner. When insulin levels are low and
fatty acid levels are high, the metabolism of fat can supply all of
the liver's energy needs. In a provocative theoretical discus-
sion, Flatt pointed out that there must be a maximum rate for
Fig. 3. Biochemical pathways in liver
connecting carbohydrate metabolism on
the left, fat oxidation in the center, and
acetate oxidation to CO2 or its incorpo-
ration into long-chain fatty acid on the
right.
beta oxidation of long-chain fatty acids and that this rate is
determined by the liver's energy utilization, since ATP cannot
be accumulated above basal amounts [16].
What are the two nonketogenic pathways of acetyl CoA
utilization in liver? As in any other tissue, the most significant
route is the condensation of acetyl CoA with oxalacetate (OAA)
in mitochondria to form citrate. Citrate formation is, of course,
the first step in the primary energy-producing series of reactions
known as the Krebs, tricarboxylic, or citric acid cycle. This
cycle regenerates oxalacetate and picks up the next acetyl CoA
for the succeeding turn of the cycle. Only acetyl groups, not the
recycling four-carbon acceptor, are oxidized by this process,
although isotopic oxidation or exchange does take place. Sub-
strates such as succinate, o-ketoglutarate, or other amino acid
analogs cannot be oxidized by the citric acid cycle but can be
converted only to OAA. Oxaloacetate can exit from the mito-
chondrion only via phosphoenol pyruvate, which, in turn, can
generate either glucose or pyruvate. In the latter case, acetyl
CoA can be generated for eventual oxidation by the citric acid
cycle. In summary, the citric acid cycle only oxidizes acetate as
acetyl CoA and produces two molecules of carbon dioxide for
each molecule of acetate.
The other route for acetyl CoA consumption is fat synthesis,
a process that also requires mitochondrial formation of citrate
(Fig. 5, Table 1). The citrate exits from the mitochondrion and
is cleaved back to OAA and acetyl CoA in the cytosol. The
acetyl CoA is carboxylated to malonyl CoA as the first step in
long-chain fatty acid synthesis. Then, catalyzed by the fatty
acid synthesis complex, the malonyl CoA units eventually form
long-chain fatty acyl CoA molecules, which are incorporated
into triglycerides. These triglycerides are exported by the liver
as very low density lipoproteins (VLDL) to the periphery,
especially adipose tissue; in adipose tissue, the triglyceride is
stored in the oil vacuole at the center of the cell.
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Fig. 4. Accentuation of gluconeogenesis
from muscle-derived amino acid (ala-
nine) and fatty acid oxidation to AcAc
and BOHB in fasting, a state with low
insulin and normal or elevated glucagon
levels.
Ketosis 419
What are the controls of acetyl CoA disposition? Nature has
devised a very simple cross-control system. When the liver is
under the influence of large amounts of insulin but low levels of
glucagon (e.g., after a carbohydrate meal), production of the
enzyme catalyzing malonyl CoA synthesis is increased and
levels of malonyl CoA increase (Fig. 5). McGarry, Mannaerts,
and Foster have shown that the increased levels of malonyl
CoA inhibit fatty acyl CoA entrance into mitochondria by
decreasing the carnitine transferase step; thus the fatty acyl
CoA moieties produced are spared from oxidation and ketone
formation and are used instead for triglyceride synthesis [6—8).
By contrast, when insulin levels are low, for example during
fasting, malonyl CoA production is decreased, and the fatty
acyl CoA molecules coming from peripherally mobilized free
fatty acids are available for ketoacid production (see Fig. 4).
How do these biochemical controls relate to glucose con-
sumption and production by the liver? Several substrates and
hormonal controls are available to direct the net flux of sub-
strate. When mitochondria are full of acetyl CoA in the low
insulin state because of fatty acid release from the periphery,
and with low levels of malonyl CoA and unchecked beta
oxidation, then citrate formation is brisk, and large quantities of
citrate exit from the mitochondria. In the cytosol, the enzyme
that cleaves citrate is low when insulin levels are low. Thus,
citrate levels increase and high levels of citrate inhibit the
principal glycolytic enzyme, phosphofructokinase. With glycol-
ysis dampened by these events, the stage is set for gluconeogen-
esis. Mitochondrial dehydrogenation of pyruvate also is inhibit-
ed because of inactivation as well as inhibition of the active
moiety of the responsible enzyme. The pyruvate that comes to
the liver from the periphery as alanine is spared oxidation to
acetyl CoA and instead is carboxylated to OAA. Thus, the
pyruvate is processed to phosphoenolpyruvate as the first step
in "reverse glycolysis" or gluconeogenesis (Fig. 4). As a result
of low insulin and probably also of normal or high glucagon
levels, all systems are directed toward gluconeogenesis [17].
For several reasons, the hepatic citric acid cycle activity is
reduced under these circumstances. Cycle activity is decreasd
first because ATP levels are ample, owing to fatty acid beta
oxidation, and OAA levels are decreased both because of
augmented incorporation into phosphoenolpyruvate and the
accumulated NADH that accelerates the formation of malate.
Second, this reduced state also inhibits the cycle by providing
less free NAD at the various dehydrogenation steps. Finally,
to return to the upper steps in glycolysis and gluconeogenesis,
inhibition of phosphofructokinase allows glucose-6-phosphate
to accumulate and results in glucose production in the liver via
the critical and unique enzyme, glucose-6-phosphatase.
Thus we can think of the liver as working in one of two
modes: a low-insulin state characterized by gluconeogenesis,
lipolysis, and ketogenesis; and a high-insulin state character-
ized by glycolysis, lipogenesis, and fat export. In the former,
the liver's energy is provided by beta oxidation of fatty acids; in
the latter state, the tricarboxylic acid cycle produces the
energy. The only exception to this rule occurs when protein is
ingested without carbohydrate (Fig. 6). When protein intake is
high, gluconeogenesis occurs, probably because of high levels
of glucagon. Yet there is little ketogenesis, and what little there
is probably results from branched-chain amino acid metabo-
lisrn. This metabolic state is probably explained by a high
insulin as well as a high glucagon level [17, 18]. Fatty acid
synthesis can proceed in humans and carnivores when the diet
VLOL
Fatty acyl CoA Malonyl CoA
:ti4
%: -> Acetyl CoA
Fatty acyl carnitine
Fatty acyl carnitine
Citrate — — -
a
Gkjcose Fatty acid
:4>
LIEttt _l
Pyruvata> - — - — Fatty acyl CoA
Acetyl CoA
Acetoacetate
3 Hyd roxybtityrate
Nutritional
state Source Disposition
High insulin Pyruvate Oxidation by tricarboxylic acid cycle
(feeding) Amino acids
Ethyl alcohol
Fatty acid synthesis
Low insulin Free fatty acids Ketoacid export
(fasting) Amino acids
Ethyl alcohol
(± acetate export)
consists of a high protein intake. A small amount of carbohy-
drate in the diet, however, suppresses glucagon production and
inhibits gluconeogenesis (Fig. 7). This observation should not
be taken to signify that insulin and glucagon are inhibitory of
each other in the liver, but that insulin also has secondary
effects independent of glucagon levels. Recent research in
phosphorylation of proteins in the liver after exposure to
insulin, glucagon, or both shows that some proteins are unique-
ly phosphorylated by each of these hormones but at different
sites and with differing metabolic effects [191. These data
support the separate messenger concept.
Ambient ketoacid levels are controlled by hepatic production
and peripheral disposition. The latter is composed of two
processes, renal excretion and oxidation by peripheral tissues,
mainly muscle but also kidney. Evidence suggests that in
prolonged ketoacidosis, renal conservation of ketoacids be-
comes more efficient [20]. Peripheral tissues, perhaps because
of increased fatty acid utilization and thus a high NAD1T1/NAD
ratio, decrease their utilization of ketoacids, as evidenced by
production of one mole of BOHB for each mole of AcAc taken
Fig. S. The high-insulin.-low-glucagon
state in which there is glycolysis to pyru-
vale, then to acetyl CoA and oxidation of
some of the acetate to CO2 via the TCA
cycle for energy. The remainder is used
for fat synthesis via export from the
mitochondria as citrate, cleavage to
CoA, and subsequently fatty acyl CoA
synthesis via the insulin-activated fatty
acid synthetase system. The fatty acyl
CoAs are used for triglyceride synthesis
and then exported from the liver as very
low density lipoprotein (VLDL).
up [21, 22]. Thus a major contribution to the ambient levels of
ketoacids is their reduced peripheral metabolism.
The physiology of ketosis. The ketoacids are derived from the
partial hepatic oxidation of long-chain fatty acids to 2-carbon
fragments, or acetate, and then are exported to other tissues
where they are oxidized. To a much lesser degree, the ketoacids
are derived from the metabolism of the branched-chain amino
acids and also can be formed from other sources of acetate,
such as ethyl alcohol. In ruminants, a considerable quantity of
acetate is produced in the rumen and in the liver from the large
load of other short-chain fatty acids, such as butyrate, coming
from the gut. In the fed state, ruminants can maintain apprecia-
ble levels of circulating ketoacids, which are utilized by skeletal
muscle and mammary tissue for the synthesis of milk fat.
Ketoacids also have another function in suckling mammalian
young including humans [9]. The medium-chain fatty acids
found in high proportion in milk enter mitochondria for oxida-
tion more readily than do long-chain fatty acids because they
bypass the carnitine transfer step and thus are not inhibited by
high levels of malonyl CoA. Mild ketoacidosis therefore can
occur in suckling animals, especially those consuming milk low
in carbohydrate, such as the carnivores. In fact, porpoise and
seal milk is almost devoid of lactose, and the pups are on a
"ketogenic" diet very high in fat and protein. What purpose
does this mild ketoacidosis serve? Increased ketoacids proba-
bly spare carbohydrate and in turn spare protein, but in these
aquatic mammals, transfer of calories as extraaqueous lipid
instead of water-soluble carbohydrate might be even more
important as a water-conserving process.
Two events in human evolution have created a relatively
unique metabolic predicament. The blood-brain barrier, shared
by all vertebrates, prevents the extracellular fluid of the central
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Table 1. Acetate (acetyl CoA) metabolism
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Fig. 6. The combined high-insulin and
high-glucagon state in which both glu-
cose synthesis (an effect of glucagon)
and fat synthesis (an effect of insulin)
occur.
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Fig. 7. Summary scheme of liver as in
Figures 3 through 6, but also containing
a scheme of mixed carbohydrate-protein
in take, in which glucagon is suppressed,
and there is net glucose intake. On the
right is the super-fasted state of diabetic
ketoacidosis in which insulin-controlled
processes are lacking.
Protein Carbohydrate
and protein
fed
nervous system from exchanging substances by simple diffusion
with the blood [23]. Numerous tight junctions bridge and
occlude the endothelial cells of the brain capillaries and pre-
clude the flux of macromolecules; only simple, small, water-
soluble molecules with specific transport processes can over-
come this barrier. Lipoprotein complexes and the albumin-fatty
acid complex are excluded from the adult human brain, and the
only remaining fuel of significant concentration in the circula-
tion that can provide calories is glucose. Glucose is thus the
standard fuel for the central nervous system in all animals
studied. At times amino acids can provide a small amount of
energy, but use of this fuel requires disposition of their amino
groups, usually as glutamine, so amino acid utilization is
relatively trivial.
The second unique evolutionary component is the dispropor-
tionate size of the human brain and its relatively large fuel
demand. In adults, the brain consumes one-fifth to one-quarter
of the total calories; in children, the brain uses as much as one-
half. Between meals, this energy demand relies on hepatic
glycogen to provide blood glucose. At most, only one day's
supply of glucose can be stored as liver glycogen, and fasting
for a longer period necessitates gluconeogenesis. The adult
Fasting Carbohydrate
fed fed
Diabetic
acidosis
id
Fatty acid VLDLVLDI
Gitico
Fatty acid .
..
A Fatty acyl CoAt——-— . fun I CoA
rvtoti
.
.. —
Acetyt CoA
AldriIn ' Py nyu Fatly acyl carn'tine tI
QuA Fatty acyl carnitine
c
Pyrtivitu Fatty acyl CeA
tochOia
: TCA Cycle
Acetoacetate
1
fl-Hydroxybutyrate
GlUCOSe
OAA
422 Nephrology Forum
brain consumes about 500 kcal daily, and that of a 5-year-old
child uses only slightly less, perhaps 450 kcal. If these calories
were derived solely from protein, about 0.5 kg of muscle would
be consumed daily. It is obvious that such total reliance on
protein would limit survival, especially in the child; but the
brain's ability to utilize selectively the increased circulating
ketoacids instead of glucose diminishes to one-fifth or one-
fourth the otherwise obligatory rate of protein breakdown [241.
Of further assistance in gluconeogenesis is the glycerol from
the lipolyzed adipose triglyceride [1, 25]. About 10% of fat by
weight is the glycerol moiety; thus, the 160 to 180 g of
triglyceride metabolized daily by a fasting human provides
about 16 to 18 g of glycerol. In addition, 10 to 15 g of glucose
can be derived from acetoacetate via acetone [14]. Thus, the
brain can even maintain some glucose utilization without rely-
ing on protein as a source. In fact, it is probably glycerol
derived from triglyceride that provides glucose for the brain in
the fasting black bear [26] and the nesting emperor penguin [27],
both of which survive months of starvation without ketosis and
without relying on gluconeogenesis. Also, their relatively small
brains contribute to their ability to survive without exogenous
protein.
The fasting human. In fasting ketosis, AcAc and BOHB
serve as a fat-derived, water-soluble fuel capable of crossing the
blood-brain barrier. Transport of these substances occurs via
facilitated diffusion, a "downhill" process, and requires an
adequate concentration of ketones in the circulation to provide
the diffusion gradient. Fasting ketosis occurs after I to 2 weeks
of starvation [1, 2, 24, 25] and is produced by a rapid increase in
hepatic production of ketones in the first few days [13—15], a
diminished peripheral utilization of ketones [21], and more
efficient renal conservation of these substances [20]. Thus with
plasma levels of BOHB and AcAc of 6—8 and 1—2 mM,
respectively, two-thirds or more of brain energy needs are
supplied. Gottstein et al have shown, by measurement of brain
arteriovenous differences during ketoacid infusion, that the
level of ketoacids determines their rate of utilization [28, 29].
The brain's dependency on ketoacids was shown in humans by
Drenick et al [30], Flatt et at [31], and Muller et al in dogs in
which glucose levels rapidly lowered with insulin produced no
subjective or objective indices of "hypoglycemia" [32]. I
should point out that fasting ketosis evolves over several days
in humans, and that this time period matches that required by
the kidney to increase ammoniagenesis [33]. One might specu-
late that the primary function of renal ammoniagenesis is to
conserve cations during fasting ketoacidosis; the parallel devel-
opment of ketosis and ammoniagenesis in fasting supports this
concept.
As ketosis becomes sufficient to provide the brain's energy
needs, glucose utilization is diminished [24]. Ruderman et al
have shown that the mechanism of decreased glucose utilization
is inhibition of phosphofructokinase by citrate, which dams up
hexose phosphate and in turn inhibits brain hexokinase [34].
The net result is the sparing of gluconeogenesis and, pan passu,
the sparing of muscle protein, extending survival time several-
fold, from weeks to months.
How does muscle sense that it no longer should provide
amino acids, primarily alanine and glutamine [35—40], for
gluconeogenesis? It has been suggested that fat oxidation
spares both ketoacid utilization [21] and perhaps the oxidation
of the keto analogs of the branched-chain amino acids [41]. If
so, resynthesis of muscle protein, inhibition of muscle break-
down, or both would be facilitated. This hypothesis is support-
ed by the observation that administration of the keto analogs of
the branched-chain amino acids in fasting humans reduces
nitrogen excretion [42, 43]. The ketoacids also might directly
contribute to this diminished proteolysis by acting as direct
inhibitors [44], but further characterization of this process is
critical, because aberrations in the normal efficiency of this
process are the basis of the hypercatabolic states associated
with trauma, sepsis, denervation disuse, and diabetic ketosis.
In summary, ketosis is a normal physiologic state in which
fat-derived, water-soluble molecules capable of crossing the
blood-brain barrier displace glucose as brain fuel. The primary
signal for ketoacid production by the liver is a low insulin level,
but ketoacid production is also modulated by formation of
acetate both from long-chain fatty acids and from other sources
such as ethyl alcohol, ketogenic amino acids, and medium- or
short-chain fatty acids in the diet.
Questions and answers
DR. JEROME P. KASSIRER: Dr. Cahill, what is the mechanism
of the rapid reversal of the metabolic abnormalities in patients
with alcoholic ketoacidosis? Typically small amounts of glu-
cose, sodium chloride, and water are all that are needed to
reverse ketosis and acidosis.
DR. CAHILL: When insulin levels are increased by glucose
infusion, ketoacid production by the liver is terminated, and
ketoacid levels fall to zero within a few hours, Also, if volume
depletion occurs, insulin release may be suppressed by adrener-
gic nerve endings in the islets of Langerhans as well as by
circulating catecholamines. Volume repletion thus is necessary
to correct this inhibition of insulin release.
As ketoacid levels fall, plasma bicarbonate rises and pH
returns to normal. This is why we are reluctant to use intrave-
nous alkali. In fact, the same principle holds true in the therapy
of diabetic ketoacidosis. We avoid using alkali unless it be-
comes absolutely necessary. Some consider a pH below 7.1 the
indication for using alkali. I prefer to make a clinical judgment.
If the patient's pulse is becoming weak, thready, and rapid, and
blood pressure is falling, then I would administer alkali. Fur-
ther, if the patient's PCO2 is 20 mm Hg or so, as a result of
hyperventilation to compensate for the metabolic acidosis, I
would be reluctant to use alkali. But if the patient is deteriorat-
ing rapidly because weakness is preventing hyperventilation,
and the PCO2 is rising as high as 35 mm Hg, alkali therapy is
indicated.
DR. KASSIRER: Under what circumstances is it appropriate to
use insulin to treat alcoholic ketoacidosis?
DR. CAHILL: These patients usually do not require insulin.
Administering intravenous glucose is usually sufficient unless
there is concomitant volume depletion; if so, dextrose and
saline should be used.
DR. JORDAN J. COHEN: It seems clear from the literature as
well as from our own experience that some individuals are
particularly susceptible to the development of alcoholic ketoac-
idosis. This is evidenced by numerous reports of recurrent
episodes in the same person and by the relatively small percent-
age of alcoholics who manifest the condition. Is there a meta-
bolic explanation for this susceptibility?
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DR. CAHILL: I can't explain this susceptibility but I do
wonder why it's so relatively rare. Despite the millions of
alcoholics who fast for days while ingesting large amounts of
ethanol, very few of these individuals appear at the hospital.
DR. JOHN T. HARRJNGTON: Is there any direct quantitative
relationship between blood ethanol levels and the severity of
the acidosis in patients who have repeated episodes of alcoholic
ketoacidosis? Secondly, can ketoacidosis be induced in normal
fasted individuals simply by infusing ethanol?
DR. CAHILL: I don't know, nor do I know whether anyone
has tried inducing ketoacidosis by giving alcohol experimentally
to fasted people.
DR. HARRINGTON: Does one ever see ketoacidosis in associa-
tion with hypoglycemia?
DR. CAHILL: Yes, especially when hypoglycemia is severe. A
large reducing load to the liver such as alcohol will reduce
oxalacetate to malate, making this substrate unavailable for
gluconeogenesis. These circumstances may lead to alcoholic
ketoacidosis complicated by severe hypoglycemia, that is, with
a blood sugar of 20 or 30 mg/dl. In this instance the most acute
problem is to treat the hypoglycemia.
DR. KASSIRER: I would like to return to the question of alkali
therapy in severe diabetic ketoacidosis and alcohol ketoacido-
sis. Although it is true that patients with severe acidosis may
recover uneventfully merely by treatment of ketosis, I have
serious reservations about withholding alkali therapy when
acidosis is extreme. Even with robust respiratory adaptation,
patients with plasma bicarbonate concentrations of 2—3 mEq/
liter typically have blood pH values less than 7.0, a state that in
itself impairs the function of many organs and threatens life.
When plasma bicarbonate concentration is this low, a further
reduction of only 1 mEq/liter, consequent to a delay in initiation
of therapy or a slight delay in response to therapy, will result in
lethal acidosis. For this reason I believe that bicarbonate
therapy is warranted in severe acidosis. The amount to give,
however, is the critical issue. I would advocate giving enough to
raise plasma bicarbonate only 4—5 mEq/liter: this increase
should raise blood pH only modestly and protect the patient. A
greater increase in plasma bicarbonate is to be avoided. Given
the propensity of hyperventilation to persist during the early
phase of correction of acidosis, a large increase in plasma
bicarbonate induced by alkali therapy can yield remarkable
alkalemia. I know that opinions differ on this issue, but do you
disagree with me?
DR. CAHILL: No, I agree with your view. But I would not
allow alkali therapy to supplant or delay attempts to expand
volume. Diabetic ketoacidosis is one of the few conditions in
medicine in which expedience is critical. It is important to insert
a large-bore needle in a large vein promptly and to administer
isotonic saline rapidly. The only other crucial factor is the
serum potassium concentration. If serum potassium is low or
even normal, potassium should be given as soon as therapy with
insulin has begun.
DR. NIcoLAos MADIAS (Renal Service, NEMC): Dr. Le-
mieux and coworkers have shown that ketone bodies depress
renal ammoniagenesis [45, 461. Do you have any thoughts about
this?
DR. CAHILL: No, I don't. I believe that the mechanisms that
control ammoniagenesis by the kidney are still an open area for
research. The controls and rate-limiting steps of ammonia
production and even the pathway for ammonia production
remain controversial.
DR. COHEN: Dr. Cahill, you noted that this patient had a
relatively low blood sugar given the degree of ketosis he had.
Some investigators claim that a small percentage of patients
with classic diabetic ketoacidosis are euglycemic [47]. Do you
agree?
DR. CAHILL: One can't have euglycemia and diabetes; it's a
matter of semantics. After a week of fasting it is possible to
have ketosis with normal blood sugar, with plasma ketone
levels as high as 6 mEq/liter. But there must be a net negative
carbohydrate loss from the body to produce more ketosis. Let
me illustrate by a small clinical "pearl": If a patient calls me in
the evening to report that her urine tests strongly for sugar, that
she cannot remember having taken her insulin in the morning,
and that she is worried about developing ketoacidosis, the
dietary history alone usually suffices to determine whether
there are grounds for concern. If the patient has eaten her usual
lunch and dinner, the chance of her having ketoacidosis is
virtually zero. In fact, she may be insulin deficient but her
glycosuria is the result of dietary "spillage": that is, her
hyperglycemia is not endogenous. If, on the other hand, the
patient failed to eat lunch and ate little at dinner, there is a
considerable probability that she is ketotic. She has sustained a
net carbohydrate loss associated with gluconeogenesis and its
accompanying ketosis. In others words, one can draw a parallel
between the net negative carbohydrate balance and the degree
of ketosis. Thus, I do not believe diabetic ketoacidosis can
develop without copious urinary spillage of endogenously de-
rived glucose.
DR. MADIAS: It has been suggested that hypophosphatemia
can cause insulin resistance and glucose intolerance [48]. In
your opinion, does hypophosphatemia have important pathoge-
netic and/or therapeutic implications for the patient with diabet-
ic ketoacidosis?
DR. CAHILL: If the patient has had chronic ketoacidosis with
substantial lean tissue loss, phosphate depletion is almost
certainly a concomitant feature. Once one gives insulin, phos-
phate moves into cells. For this reason potassium should be
given as the phosphate salt. I am not convinced that administer-
ing phosphate ordinarily is critical, but if the individual is
debilitated, I prefer to give potassium as phosphate rather than
as chloride.
DR. COHEN: The starving person who uses ketone bodies
instead of glucose to fuel the brain must, as a consequence,
develop some degree of acidosis. Is there any metabolic advan-
tage to the acidosis per se?
DR. CAHILL: That is an important question, because ketosis
is the basis of the protein-sparing effect of modified fast.
Namely, if one completely deprives people of food and then
gives them a little bit of protein, they maintain nitrogen balance.
But the process is very inefficient. One has to administer
approximately 80 to 100 grams of protein to spare about 20
grams. This 20 grams would be lost if no protein were given.
DR. COHEN: There is no reason, I gather, to think that the
inevitable acidosis is advantageous.
DR. CAHILL: No, but there are normal people in the world
who are chronically acidotic. The blubber-eating eskimo is the
prototype.
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DR. COHEN: As illustrated by today's patient, the ratio of -
hydroxybutyric acid to acetoacetic acid is unusually high in
alcoholic ketoacidosis. This circumstance often poses a diag-
nostic problem on the wards because the nitroprusside reaction
does not detect 3-hydroxybutyrate. Is there any convenient
way for the clinician or, for that matter, the routine clinical
laboratory to estimate the concentration of this substance?
DR. CAHILL: The best approach is to measure plasma bicar-
bonate concentration and obtain a rough estimation of acetoac-
etate using one of the crude bedside tests. A positive acetoace-
tate level and a very low plasma bicarbonate concentration
suggest ketosis with a high level of f3-hydroxybutyrate. The
combination of a barely positive acetoacetate test and a very
low plasma bicarbonate concentration signifies either a very
reduced state with high concentrations of 3-hydroxybutyrate or
else a coincidental lactic acidosis, Fortunately, as far as treat-
ment is concerned, it does not make too much difference
because therapy is directed at correcting volume deficiency, at
returning blood sugar toward normal with insulin, and at
correcting acidosis with alkali if the situation is life threatening.
Reprint requests to Dr. George F. Cahill, Jr., Howard Hughes
Medical Institute, 398 Brookline Avenue, Boston, Mass., 02215 USA
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